Parise L V, Venton D L, Le Breton G C
J Pharmacol Exp Ther. 1984 Jan;228(1):240-4.
The mechanism by which the active metabolites of arachidonic acid (AA), i.e., thromboxane A2 and/or prostaglandin H2 (TXA2/PGH2) induce platelet aggregation is not understood. Several reports have suggested that AA-stimulated aggregation is mediated by secreted ADP, whereas other studies have proposed that this response is ADP-independent. In the present report, we used the specific TXA2/PGH2 receptor antagonist, 13-azaprostanoic acid (13-APA), and the ADP antagonist, ATP, to examine the contribution of TXA2/PGH2 or secreted ADP to aggregation. We found that 13-APA, but not ATP, deaggregates platelets stimulated by AA or U46619 (a TXA2/PGH2 mimetic). In contrast, ADP-induced aggregation was reversed in response to ATP but not to 13-APA. These results suggest that TXA2/PGH2-stimulated aggregation is mediated through TXA2/PGH2 receptor occupation. Furthermore, secreted ADP does not appear to be required for maintenance of the AA-aggregation response.
花生四烯酸(AA)的活性代谢产物,即血栓素A2和/或前列腺素H2(TXA2/PGH2)诱导血小板聚集的机制尚不清楚。一些报告表明,AA刺激的聚集是由分泌的ADP介导的,而其他研究则提出这种反应不依赖于ADP。在本报告中,我们使用了特异性TXA2/PGH2受体拮抗剂13-氮杂前列腺酸(13-APA)和ADP拮抗剂ATP,来研究TXA2/PGH2或分泌的ADP对聚集的作用。我们发现,13-APA而非ATP能使由AA或U46619(一种TXA2/PGH2模拟物)刺激的血小板解聚。相反,ADP诱导的聚集在加入ATP后会逆转,但加入13-APA后不会。这些结果表明,TXA2/PGH2刺激的聚集是通过TXA2/PGH2受体的占据来介导的。此外,维持AA诱导的聚集反应似乎不需要分泌的ADP。